Clarity Pharmaceuticals (ASX:CU6) logged a AU$0.291 loss per share for fiscal 2026, compared with a loss of AU$0.201 a year ago, a Thursday filing showed.
For the 12 months ended June 30, revenue from ordinary activities was AU$8 million, which the Australia-listed developer of radiopharmaceutical diagnostics products said was up 68% from a year earlier.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.